- BioNxt Solutions (BNXT, BNXTF, BXT) continues to navigate a Management Cease Trade Order (MCTO) by the British Columbia Securities Commission.
- The company plans to file its delayed 2024 annual financial statements by June 30, 2025.
- Shareholder trading abilities remain unaffected despite trading restrictions on the CEO and CFO.
BioNxt Solutions Inc. (BNXT, BNXTF, BXT), a bioscience innovator, has issued an update regarding its Management Cease Trade Order (MCTO) initiated by the British Columbia Securities Commission on May 1, 2025. This MCTO restricts the company's Chief Executive Officer and Chief Financial Officer from trading in company securities until the company files its annual audited financial statements and related documents for the year ended December 31, 2024.
The company has made significant progress in addressing the delay, having received all necessary audit materials from its German subsidiaries and prepared draft financials for auditor review. BioNxt is aiming to meet a filing deadline of June 30, 2025, for these required documents. Meanwhile, the MCTO does not impact the trading ability of shareholders, allowing them to continue trading their shares without interruption.
BioNxt Solutions has confirmed that there have been no material changes to its operations since the initial Default Announcement, and it remains committed to rectifying the filing delay with its auditors. The company is cooperating fully towards resolving any outstanding issues and is intent on maintaining compliance with regulatory standards.
